Polycystic Ovary Syndrome
Conditions
Interventions
Gold Standard:Clinical diagnosis meet the 2003 Rotterdam diagnostic criteria for Polycystic Ovary Syndrome patient
Sponsors
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Polycystic Ovary Syndrome group: 1. meet the 2003 Rotterdam diagnostic criteria: (1) patients with rare ovulation or even no ovulation (this study is defined as clinical manifestations of more than 1 year irregular menstruation and menstrual cycle > 35 days or < 21 days); (2) The clinical symptoms or biochemical manifestations of the patient showed hyperandrogenism; (3) Ultrasound showed polycystic changes in the ovary (ultrasound showed that the number of follicles containing 2-9 mm on one or both sides of the ovary was greater than 12, and/or ovarian volume = 10 ml); A diagnosis can be made by meeting two of the above three criteria and excluding other hyperandrogenism. 2. Women between the ages of 18 and 40 years; Control group: healthy women aged 18 to 40 years old were selected for normal physical examination, normal ovulation, regular menstruation, gynecological ultrasound and normal sex hormone test results.
Exclusion criteria
Exclusion criteria: (1) used any hypoglycemic, lipid-lowering, antihypertensive and hormonal drugs in the past 3 months; (2) People with severe allergies or recent infections; (3) Pregnant and lactating women; (4) Endocrine and gynecological diseases such as congenital adrenal hyperplasia, Cushing's syndrome, and androgen-secreting tumors, etc., which cause elevated androgen; (5) Those suffering from other diseases such as heart, liver and kidney, and blood system diseases; (6) suffering from other diseases that cause ovulation disorders (such as hyperprolactinemia, pituitary or hypothalamic amenorrhea, ovarian insufficiency, proliferation of ovarian membrane cells; uterine fibroids and endometriosis), Autoimmune diseases, diabetes, history of radiotherapy and chemotherapy, and thyroid dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| anti-Mullerian hormone;antral follicle Number (2-9mm);ovarian volume; | — |
Secondary
| Measure | Time frame |
|---|---|
| height;weight;body mass index;waist-to-hip ratio;follicle stimulating hormone;luteinizing hormone;prolactin;estrogen;dehydroepiandrosterone sulfate;androstenedione;testosterone;Sex hormone binding protein;total cholesterol;triglyceride;high density lipoprotein;low density lipoprotein;apolipoprotein-A;apolipoprotein-B;lipoprotein;glycated hemoglobin;blood sugar;insulin; | — |
Countries
China
Contacts
Public ContactLiu Yi
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed